“I will never give up!”
Nobel laureate Robert Koch (1843 – 1910)
German physician and microbiologist,
discovered the Tuberculosis pathogen in 1882.
Who We Are
Austrianni GmbH is a pharmaceutical company with the mission to develop therapeutics for the prevention and treatment of tuberculosis.
We’ll do whatever it takes to generate new drugs for tuberculosis therapy. These drugs are either chemicals or biologicals, e.g., antibiotics or human antibodies. Traditionally, the discovery of either one of these medicines has required large teams, but recently, dedicated contract research organizations have taken over important parts of the processes. This allows us to concentrate on our core competencies that we have assembled in our company.
Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human antibody variable domains, which undergo natural V(D)J recombination and somatic hyper-mutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.
There are many enzymes that Mycobacterium tuberculosis cannot live without, and several antibiotics exploit this fact. Traditionally, antibiotics were found by testing large collections of microorganisms, or large collections of chemicals, for their ability to interfere with bacterial growth. Or chemical libraries were tested against an isolated target. In either case, only a tiny fraction of the vast chemical space of drug-like structures, estimated to consist of 1063 structures, can be covered.
Austrianni has unrestricted access to the powerful antibody discovery platform developed by the California company Trianni. This platform features the complete diversity of human anti-body variable domains, which undergo natural V(D)J recombination and somatic hyper-mutation. Using this platform, Austrianni isolates fully human antibody therapeutics for the treatment of tuberculosis, with emphasis on multidrug resistant tuberculosis.
Members of the Austrianni team take part in conferences dedicated to the investigation of the host-pathogen relationship in TB, and in other conferences that deal with the biotech, pharma and healthcare business. In the following, some of these upcoming events are listed.
Postponed to September 2022
EMBO Tuberculosis 2020: From innovation to intervention
As the global situation with TB is unfortunately still very far from being solved despite some major scientific advances in recent years, and TB still remains a key infectious disease that globally claims more than 4000 human lives every day, the search for novel, scientifically very challenging, solutions to this human tragedy are of urgent and continued interest. Thus, the objectives of this meeting are to unite a critical mass of scientists involved in research to communicate and exchange novel information on the disease and the causative agent, as well as related mycobacteria that are of medical interest.
13 – 16 September 2022
Durban, South Africa
7th SA TB Conference 2022
Aims of the conference :
Re-energise the TB community through in-person interaction of academic, governmental, non-governmental and civil society stakeholders.
Understand setbacks in TB control and research due to the Covid-19 epidemic and examine opportunities to get back on track.
Understand the latest advances in TB prevention, diagnosis, and treatment, including discovery, development, and implementation.
Explore optimal community engagement and communications in TB control and research. Social aspects around TB
Learn about advances in basic understanding of the pathogen and host response
© 2019 AUSTRIANNI. All rights reserved.